News

A Successful PAI for a new Peptide Drug from Japan PMDA

Our peptide manufacturing facility at Changzhou site has successfully passed the Pre-Approval Inspection by Japan Pharmaceuticals and Medical Devices Agency (PMDA) for an innovative peptide drug. The 3-day inspection, without any major findings, highlighted our commitment to quality and excellence in peptide production.

Since January 2024, we’ve tripled our solid-phase peptide synthesis capacity to more than 32,000 L across our Changzhou and Taixing sites, and more capacities will be added in Taixing and Singapore to accelerate peptide drugs to patients.

Scroll to Top
Please enable JavaScript in your browser to complete this form.
Checkboxes